• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康差异对局部食管腺癌拒绝三联疗法的影响:国家癌症数据库的倾向评分匹配分析。

Effect of Health Disparities on Refusal of Trimodality Therapy in Localized Esophageal Adenocarcinoma: A Propensity Score Matched Analysis of the National Cancer Database.

机构信息

Department of Surgical Oncology, Edward-Elmhurst Health, Naperville, IL, USA.

Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.

出版信息

Am Surg. 2023 Nov;89(11):4644-4653. doi: 10.1177/00031348221117040. Epub 2022 Sep 16.

DOI:10.1177/00031348221117040
PMID:36112751
Abstract

BACKGROUND

Factors associated with refusal of multimodality therapy in patients with localized esophageal adenocarcinoma (EA) remain unknown. We hypothesized that sociodemographic disparities affect decision to pursue optimal trimodally therapy for patients with EA.

METHODS

NCDB for esophageal cancer (2004-2017) was utilized. Included were patients diagnosed with cT3-T4 cN0 or cTany N1-3 EA of the mid-lower esophagus. Annual institutional esophagectomy volumes were categorized as low (<20/year) and high (≥20/year). Conditional logistic regression was used to identify predictors of refusal of offered treatment. Kaplan Meier method was used to compare survival.

RESULTS

13 091 patients met selection criteria, mean age was 62.4 ± 9.6 years and 11 581 (88.5%) were males. 633 (4.8%) patients refused at least one component of recommended treatment (chemotherapy, radiation, and esophagectomy), most commonly refusal of surgery (N = 554, 4.2%). On multivariable analysis, factors predictive of treatment refusal included older age, female gender, black race, no insurance, low income (below poverty), mid-esophageal tumors, and treatment at low-volume centers. Patients who were recommended treatment but refused had significantly worse survival than those who adhered to treatment (median 23.1 ± 1.1 vs. 32.1 ± 1.2 months; < .001).

CONCLUSIONS

In this study, sociodemographic disparities and center volume were among factors predictive of therapy refusal in patients with localized esophageal adenocarcinoma. While understanding potential reasons for treatment refusal is critical, this data suggests that socioeconomic variables may drive patient decisions.

摘要

背景

局部食管腺癌 (EA) 患者拒绝多模式治疗的相关因素尚不清楚。我们假设社会人口统计学差异会影响 EA 患者接受最佳三联治疗的决定。

方法

利用 NCDB 食管癌数据库(2004-2017 年)。纳入标准为 cT3-T4 cN0 或 cTany N1-3 中下段食管 EA 患者。每年机构食管癌切除术的量分为低(<20/年)和高(≥20/年)。使用条件逻辑回归来确定拒绝提供的治疗的预测因素。Kaplan-Meier 方法用于比较生存情况。

结果

13091 名患者符合入选标准,平均年龄为 62.4±9.6 岁,11581 名(88.5%)为男性。633 名(4.8%)患者拒绝了至少一种推荐治疗方法(化疗、放疗和食管癌切除术),最常见的是拒绝手术(N=554,4.2%)。多变量分析显示,预测治疗拒绝的因素包括年龄较大、女性、黑人、无保险、低收入(低于贫困线)、中段食管肿瘤和低容量中心治疗。被推荐治疗但拒绝治疗的患者的生存时间明显短于接受治疗的患者(中位数 23.1±1.1 与 32.1±1.2 个月;<.001)。

结论

在这项研究中,社会人口统计学差异和中心容量是预测局部食管腺癌患者治疗拒绝的因素之一。虽然了解治疗拒绝的潜在原因至关重要,但这些数据表明,社会经济变量可能会影响患者的决策。

相似文献

1
Effect of Health Disparities on Refusal of Trimodality Therapy in Localized Esophageal Adenocarcinoma: A Propensity Score Matched Analysis of the National Cancer Database.健康差异对局部食管腺癌拒绝三联疗法的影响:国家癌症数据库的倾向评分匹配分析。
Am Surg. 2023 Nov;89(11):4644-4653. doi: 10.1177/00031348221117040. Epub 2022 Sep 16.
2
Consequences of Refusing Surgery for Esophageal Cancer: A National Cancer Database Analysis.拒绝手术治疗食管癌的后果:国家癌症数据库分析。
Ann Thorac Surg. 2018 Nov;106(5):1476-1483. doi: 10.1016/j.athoracsur.2018.06.030. Epub 2018 Jul 25.
3
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.食管癌的根治性或术前放化疗:治疗模式与生存结果
Ann Thorac Surg. 2016 Jun;101(6):2148-54. doi: 10.1016/j.athoracsur.2015.12.056. Epub 2016 Mar 24.
4
Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.高强度调强放疗在大容量中心改善了接受三联疗法的食管腺癌患者的生存。
Dis Esophagus. 2019 Aug 1;32(8). doi: 10.1093/dote/doy124.
5
Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.接受三联疗法的食管腺癌患者的生存率与区域淋巴结位置无关。
Ann Thorac Surg. 2016 Mar;101(3):1075-80; Discussion 1080-1. doi: 10.1016/j.athoracsur.2015.09.063. Epub 2015 Dec 8.
6
Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival.拒绝局部治疗食管癌及其对总生存的影响。
Ann Surg Oncol. 2021 Feb;28(2):663-675. doi: 10.1245/s10434-020-08761-7. Epub 2020 Jul 9.
7
Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer.食管癌切除术前进行诱导放化疗与更好的长期生存率相关。
Dis Esophagus. 2015 Nov-Dec;28(8):788-96. doi: 10.1111/dote.12285. Epub 2014 Sep 12.
8
Disparities in survival after trimodality therapy for esophageal adenocarcinoma.食管腺癌三联疗法后的生存差异。
Dis Esophagus. 2018 Sep 1;31(9). doi: 10.1093/dote/doy020.
9
Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.新辅助放化疗可改善老年食管癌患者的总生存。
J Geriatr Oncol. 2018 Jan;9(1):40-46. doi: 10.1016/j.jgo.2017.08.010. Epub 2017 Sep 6.
10
More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer.不止是治疗拒绝:国家癌症数据库分析子宫内膜癌患者辅助治疗拒绝与种族生存差异。
Am J Obstet Gynecol. 2022 Aug;227(2):244.e1-244.e17. doi: 10.1016/j.ajog.2022.03.004. Epub 2022 Mar 10.

引用本文的文献

1
Refusal of Adjuvant Therapies and Its Impact on Local Control and Survival in Patients with Bone and Soft Tissue Sarcomas of the Extremities and Trunk.肢体和躯干骨肉瘤及软组织肉瘤患者辅助治疗的拒绝及其对局部控制和生存的影响
Cancers (Basel). 2024 Jan 5;16(2):239. doi: 10.3390/cancers16020239.
2
The impact of refusing esophagectomy for treatment of locally advanced esophageal adenocarcinoma.拒绝进行食管切除术治疗局部晚期食管腺癌的影响。
JTCVS Open. 2023 Sep 14;16:987-995. doi: 10.1016/j.xjon.2023.09.006. eCollection 2023 Dec.